Advertisement
ENGN vs PHAR
Which Stock Would AI Choose? enGene Holdings (ENGN) vs. Pharming Group (PHAR) Stock Comparison
Key Takeaways
- ENGN is a clinical-stage, pre-revenue biotech focused on non-viral genetic medicines, while PHAR is a commercial-stage rare-disease company with growing revenue and profitability.
- Tickeron AI Verdict: PHAR is the favored ticker, reflecting its commercial revenue base, positive earnings, and comparatively more stable trend versus ENGN's binary, pre-approval risk profile.
- PHAR carries analyst "Strong Buy" consensus and positive catalysts around its Joenja therapy expansion, while ENGN remains dependent on clinical and regulatory milestones.
- For more detail on the latest developments, explore ENGN Major News and ENGN Today's Price Move, plus PHAR Major News and PHAR Today's Price Move.
- To see how automated strategies are currently positioned across the market, explore Trending AI Robots.
Introduction
This stock comparison examines two biotechnology names at very different stages of the corporate lifecycle: ENGN, a clinical-stage developer of genetic medicines, and PHAR, a commercial-stage rare-disease company already generating revenue and profit. Because the two firms diverge sharply in maturity, risk, and momentum, their relative performance offers a useful lens for investors weighing high-risk clinical upside against more established, revenue-generating operations. Growth-oriented and speculative traders may find ENGN's binary catalysts compelling, while investors seeking stability and demonstrated commercialization may gravitate toward PHAR.
ENGN Overview and Recent Performance
ENGN is enGene Holdings Inc., a clinical-stage biotechnology company developing non-viral genetic medicines delivered to mucosal tissues and other organs through its proprietary DDX (dually derived chitosan) platform. Its lead candidate, detalimogene voraplasmid, is being studied in the Phase 2 LEGEND trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). BCG (Bacillus Calmette-Guérin) is the standard first-line bladder-cancer immunotherapy, and "BCG-unresponsive" describes patients whose disease has not responded to it.
In recent market activity, ENGN has traded well below its 52-week highs, reflecting a substantial drawdown as a pre-revenue company with a market capitalization in the low hundreds of millions. The company has indicated plans to submit a Biologics License Application (BLA) to the U.S. FDA, positioning regulatory milestones as key drivers of sentiment. With negative earnings per share (EPS) and no commercial revenue, the stock's behavior has been shaped primarily by clinical data updates, trial-enrollment developments, and broader risk appetite for speculative biotech.
PHAR Overview and Recent Performance
PHAR is Pharming Group N.V., a Netherlands-based biopharmaceutical company that develops and commercializes protein-replacement and precision therapies for rare diseases. Its lead products include RUCONEST, a recombinant C1 esterase inhibitor for hereditary angioedema (HAE), a condition causing recurrent swelling attacks, and Joenja (leniolisib), an oral PI3Kδ inhibitor for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immune disorder. The company reports revenue in the high hundreds of millions on a trailing twelve-month (TTM) basis and has returned to profitability.
In recent weeks, PHAR has demonstrated a rebound in price momentum following a period of weakness earlier in the year. Recent catalysts include the U.K. MHRA's approval of Joenja for children with APDS and third-quarter revenue growth driven by RUCONEST stability and Joenja's international expansion. The company also announced a mutual agreement for its CEO to step down, a leadership transition investors have weighed alongside its commercial execution. With "Strong Buy" analyst consensus and a price target well above current levels, sentiment toward PHAR reflects confidence in its revenue diversification.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-powered trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of different tickers, but only those best suited to current market conditions earn a place in this rotating, curated section. Each bot operates with its own trading style, strategy, timeframe, performance record, and statistical profile, and targets a distinct set of tickers. This variety allows users to explore automated approaches ranging from short-term momentum strategies to longer-horizon trend-following systems. For traders seeking a systematic, data-driven way to evaluate setups such as the ENGN versus PHAR comparison, reviewing the Trending AI Robots can offer additional, quantified perspective.
Head-to-Head Comparison
The clearest contrast between the two names is business maturity. PHAR is commercial-stage, generating revenue and positive net income, which provides a financial buffer and more predictable cash flows. ENGN, by contrast, is pre-revenue and depends on clinical success and regulatory approval to reach commercialization, giving it a fundamentally higher-risk profile.
Their growth drivers also differ. ENGN's investment case rests on a single lead candidate and its potential FDA pathway, creating concentrated, event-driven risk. PHAR's growth is spread across two commercialized products and geographic expansion, offering more diversified catalysts. On momentum, PHAR has shown relative stability and a recent rebound, while ENGN has experienced deeper volatility typical of early-stage biotech. Both are small- to mid-cap healthcare names sensitive to sector sentiment, but their risk-reward profiles are materially different.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue stability, earnings quality, and the presence of diversified catalysts, Tickeron's AI would currently lean toward PHAR over ENGN. PHAR's commercial revenue, profitability, and comparatively steadier market positioning provide a more consistent trend profile, whereas ENGN's outlook hinges on binary clinical and regulatory outcomes that introduce greater uncertainty. This assessment is probabilistic and reflects current market conditions rather than a definitive forecast; shifts in clinical data, approvals, or broader biotech sentiment could alter the relative positioning of the two names over time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENGN is a Buy and PHAR is a Buy.
ENGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 02, 2026
ENGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 21 of 23 cases where ENGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENGN's RSI Indicator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ENGN as a result. In 48 of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for ENGN just turned positive on November 04, 2026. Looking at past instances where ENGN's MACD turned positive, the stock continued to rise in 21 of 27 cases over the following month. The odds of a continued upward trend are 78%.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENGN advanced for three days, in 129 of 152 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
ENGN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENGN crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ENGN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.509) is normal, around the industry mean (3.498). P/E Ratio (-0.845) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ENGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for PHAR turns positive, indicating new upward trend
PHAR saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 111 similar instances where the indicator turned positive. In 93 of the 111 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PHAR just turned positive on October 20, 2026. Looking at past instances where PHAR's MACD turned positive, the stock continued to rise in 48 of 61 cases over the following month. The odds of a continued upward trend are 79%.
PHAR moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PHAR crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +7.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAR advanced for three days, in 168 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
PHAR broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PHAR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PHAR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.216) is normal, around the industry mean (3.498). PHAR has a moderately high P/E Ratio (88.107) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.080) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.168) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
PHAR | ||
|---|---|---|
OUTLOOK RATING 1..100 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 75 | |
SMR RATING 1..100 | 86 | |
PRICE GROWTH RATING 1..100 | 40 | |
P/E GROWTH RATING 1..100 | 96 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ENGN | PHAR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 72% |
| Advances ODDS (%) | 3 days ago 85% | 2 days ago 71% |
| Declines ODDS (%) | 20 days ago 82% | 6 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENGN’s FA Score shows that 0 FA rating(s) are green while PHAR’s FA Score has 0 green FA rating(s).
- ENGN’s FA Score: 0 green, 5 red.
- PHAR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENGN’s TA Score shows that 5 TA indicator(s) are bullish while PHAR’s TA Score has 5 bullish TA indicator(s).
- ENGN’s TA Score: 5 bullish, 5 bearish.
- PHAR’s TA Score: 5 bullish, 5 bearish.
Price Growth
ENGN (@Biotechnology) experienced а +3.09% price change this week, while PHAR (@Biotechnology) price change was +2.24% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
ENGN is expected to report earnings on Dec 28, 2026.
PHAR is expected to report earnings on Mar 18, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ENGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ENGN has been closely correlated with TRDA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if ENGN jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To ENGN | 1D Price Change % | ||
|---|---|---|---|---|
| ENGN | 100% | -5.65% | ||
| TRDA - ENGN | 75% Closely correlated | +11.94% | ||
| COGT - ENGN | 48% Loosely correlated | -5.66% | ||
| PHAR - ENGN | 43% Loosely correlated | +0.46% | ||
| INSM - ENGN | 42% Loosely correlated | +2.92% | ||
| ASBP - ENGN | 36% Loosely correlated | +0.06% | ||
More | ||||
PHAR and
Correlation & Price change
A.I.dvisor indicates that over the last year, PHAR has been loosely correlated with TRDA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAR jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To PHAR | 1D Price Change % | ||
|---|---|---|---|---|
| PHAR | 100% | +0.46% | ||
| TRDA - PHAR | 44% Loosely correlated | +11.94% | ||
| ENGN - PHAR | 43% Loosely correlated | -5.65% | ||
| LKFT - PHAR | 36% Loosely correlated | -0.33% | ||
| INSM - PHAR | 34% Loosely correlated | +2.92% | ||
| LGND - PHAR | 33% Loosely correlated | +0.00% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XLCI | 22.69 | 0.09 | +0.38% |
| State Street Communication Services Select Sector SPDR Premium Income ETF (XLCI) | |||
| OPER | 100.17 | 0.01 | +0.01% |
| ClearShares Ultra-Short Maturity ETF (OPER) | |||
| NVBT | 40.07 | -0.10 | -0.25% |
| AllianzIM U.S. Equity Buffer10 Nov ETF (NVBT) | |||
| AVIG | 39.96 | -0.28 | -0.70% |
| Avantis Core Fixed Income ETF (AVIG) | |||
| ICOP | 47.94 | -1.52 | -3.07% |
| iShares Copper and Metals Mining ETF (ICOP) | |||